Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Stony Brook based Viatronix Incorporated, developer of 3D imaging software, has announced the publication of a new study utilizing the Viatronix V3D- Colon platform exclusively. Stony Brook based Viatronix Incorporated, developer of 3D imaging software, has announced the publication of a new study in the New England Journal of Medicine, titled 'CT Colonography versus Colonoscopy for the Detection of Advanced Neoplasia'. The study utilized the Viatronix V3D- Colon platform exclusively.

The results published in the October 4th issue of the New England Journal of Medicine compared primary CTC screening in 3,120 adults with primary OC screening in 3,163 adults and found that primary CTC and OC for colon cancer screening provide similar detection rates for advanced neoplasia. Although the number of polypectomies and complications were considerably smaller in the CTC group. The study was conducted at the University of Wisconsin by Pickhardt et al., and concluded that the results support the use of CTC as a primary screening test before therapeutic OC. This once again proves that CTC screening with the Viatronix V3D-Colon is a safe, clinically effective, and cost-effective technique for colon cancer screening.